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ABSTRACT
We studied bone mineral density (BMD) in 79 long-term survivors of allogeneic stem cell transplantation
(SCT) (median follow-up: 78 months; range: 38-160). Seventy patients received a total body irradiation
(TBI)-based myeloablative SCT and 9 patients received a non-TBI, reduced-intensity SCT. Fourteen (18%)
patients were receiving immunosuppressive therapy (IST) for chronic graft-versus-host disease (cGVHD)
beyond 3 years from SCT. Fifty-eight (73.4%) of patients had bone loss (BL): 33 (41.8%) with osteopenia and
25 (31.6%) with osteoporosis. Factors associated with a significantly increased risk of osteoporosis were age
and prolonged IST and for overall BL prolonged IST. However, BL was not associated with an increased
fracture risk, despite the fact that most patients had not received prophylactic biphosphonates. Our data shows
that BL is a long-term posttransplant complication, and emphasize the importance of serial BMD scans, and
the treatment of BL with biphosphonates reserved for worsening BL or additional risk factors.
© 2007 American Society for Blood and Marrow Transplantation
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PNTRODUCTION
As stem cell transplantation (SCT) becomes safer,
early 90% of patients alive 2 years after allo-SCT
ill become long-term survivors [1]. As patients age
fter transplant, the focus of care moves from cure of
he original disease to the identiﬁcation and treatment
f delayed and long-term complications that can
ffect quality of life. Chronic graft-versus-host dis-
ase (cGVHD) has attracted the most attention, but
arge database analyses identify signiﬁcant frequencies
f other problems such as hypothyroidism, secondary
ancer, and pulmonary complications in long-term
urvivors. Consecutive follow-up of long-term survi-
ors after allo-SCT is, however, lacking. In 2005, we
herefore initiated a follow-up study for long-term
urvivors of allo-SCT. Patients were enrolled at the lhird annual visit after transplantation. Annual screen-
ng includes evaluation for cGVHD, major organ dys-
unction, secondary malignancies, hormonal proﬁle,
ertility, and quality of life.
In this analysis we evaluated bone mineral density
BMD) in long-term survivors. Bone loss (BL) after
CT has been described but mainly at earlier time
oints [2-4]. Here, we describe site-speciﬁc BL and
isk factors in a patient cohort with a median survival
osttransplant exceeding 5 years.
TUDY DESIGN
atients and Methods
Four hundred seventeen patients with hemato-
ogic disorder received SCT from an HLA identical
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B. N. Savani et al.518ibling in our institute between 1993 and 2003. We
arried out a cross-sectional study on a group of pa-
ients enrolled at a minimum of 3 years posttransplan-
ation between April 2005 and October 2006, in an
nstitutional review board-approved long-term evalu-
tion protocol (05-H-0130). Of 111 patients surviving
or more years at the initiation of study in 2005, 84
76%) patients gave written informed consent ac-
ording to principles outlined in the Declaration of
elsinki, and 79 underwent dual energy X-ray ab-
orptiometry (DEXA) scanning to determine BMD.
iagnoses were chronic myelogenous leukemia
CML) (46), myelodysplastic syndrome (MDS) (13),
cute myelogenous leukemia (AML) (12), acute lym-
hoblastic leukemia (ALL) (3), chronic lymphocytic
eukemia (CLL) (2), severe aplastic anemia (1), mas-
ocytosis (1), and multiple myeloma (1). Seventy (me-
ian age 35 years) received a myeloablative stem cell
ransplantation (MST). Conditioning consisting of to-
al-body irridiation (TBI) 12-13.6 Gy and cyclophos-
hamide (ﬂudarabine) with a T cell-depleted bone
arrow transplantation (BMT) (14) or peripheral
lood stem cell transplantation (PBSCT) (56) and
yclosporine as GVHD prophylaxis. Nine received a
on-TBI reduced intensity regimen (RIC) (median
ge: 37 years) of ﬂudarabine 125 mg/m2 and cyclo-
hosphamide 60 mg/kg, followed by a PBSCT with
yclosporine as GVHD prophylaxis.
Bone mineral density was measured by DEXA at 7
natomic sites (Table 1). Both T- and Z-scores were
easured in adult patients and the Z-score in children
5). Patients were advised to take vitamin D and calcium
upplements after SCT. All but 1 female and no male
atients were taking hormonal replacement therapy.
wo patients (aged 61 and 65 years) continued taking
iphosphonates given before SCT for osteoporosis. Ra-
iologic evaluations for fractures were performed when
linically indicated only in symptomatic individuals.
efinitions
Bone mineral density results were expressed as the
umber of standard deviations from normal values of
oung, healthy, gender-matched controls (T-score)
nd from normal values of age- and gender-matched
able 1. Site-Speciﬁc Incidence of Bone Loss
Site Osteopenia Osteoporosis
P spine 18 (23%) 14 (18%)
emoral neck 36 (46%) 6 (8%)
emur (T) 26 (33%) 3 (4%)
emur (IT) 26 (33%) 2 (3%)
emur (W) 28 (35%) 7 (9%)
otal hip 28 (35%) 3 (4%)
orearm 19 (24%) 11 (14%)
P indicates anterior–posterior; T, trochanteric; IT, intertrochan-
pteric; W, ward.ontrols (Z-score). World Health Organization crite-
ia for BMD were used. We classiﬁed patients as
ormal (T-score  1), osteopenia (T-score  1
nd  2.5), and osteoporosis (T-score  2.5).
aking the broad age range of the study population,
or children and adolescents, the Z-score was used to
eﬁne the BL (osteopenia—Z-scores between 1 and 2,
D below the mean; osteoporosis—Z-score 2 SD
elow the mean) to avoid the underestimation. An-
ther reason for selecting the T-score in adults over
he Z-score is that the T-score has been shown to be
he most relevant indicator of fracture risk in adults or
lder individuals [5-7].
tatistical Analysis
Analysis was performed in November 2006. The
isk factors inﬂuencing BL were determined by uni-
ariate and multivariate analyses of various clinical and
ransplant factors of patients with and without BL. In
nivariate analyses, chi-squared tests or Fisher’s exact
ests were used for categoric variables where appro-
riate, and the Mann-Whitney U-test was used for
ontinuous variables. Logistic regression was used for
ultivariate analysis, which included factors found to
e signiﬁcant in univariate analyses. Statistical signif-
cance was accepted at P  .05. The following vari-
bles were analyzed to identify factors associated with
L in long-term survivors: age (as a continuous or
iscontinuous variable); gender; diagnosis; BMT ver-
us PBSCT, TBI versus no TBI, TBI dose 12 versus
3.6 Gy; disease risk (standard or high); follow-up
continuous,  versus  median; 10 versus 10 years
ollow-up); acute GVHD (aGVHD), cGVHD, pro-
onged immunosuppressive therapy (IST) (beyond 3
ears posttransplant). Analysis was performed sepa-
ately for factors associated with overall BL (develop-
ent of osteoporosis or osteopenia) and osteoporosis.
ESULTS
Age of patients at transplantation ranged from
-66 years (median: 35). Thirty-three patients were
emale and 46 were male. Seventy-seven (97%) are
live after median follow-up 78 months (range: 38-
60) post-SCT. Two patients died from nonrelapse
auses or progressive leukemia at 39 and 59 month’s
ost-SCT, respectively. aGVHD grades II-IV oc-
urred in 15 (19%) patients and chronic GVHD
n 63 (79.7%) (limited—47 [59.5%]; extensive—16
20.2%]). Fourteen (18%) were on immunosuppres-
ion at the time of DEXA scanning at a median fol-
ow-up 42 months (range: 38-108).
L
Bone loss occurred in 58 (73.4%) patients; 33
41.8%) with osteopenia and 25 (31.6%) with osteo-
orosis. However, no patient suffered fractures related
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Bone Loss following Allogeneic Stem Cell Transplantation 519o BL. The mean T-score of adult patients was1.8
.18 (male: 1.9  0.2; female: 1.6  0.5); whereas
he mean Z-score of 5 children (age:18) was1.6
.45. Site-speciﬁc BL is described in Table 1. There
as a preponderance of osteopenia and osteoporosis
n typical sites such as AP spine (23% and 18%),
emoral neck (46% and 8%), femur (Ward’s area)
35% and 9%), and total hip (35% and 4%), but also
n the forearm (24% and 14%).
actors Associated with BL
On univariate analysis signiﬁcant factors for over-
ll BL was prolonged IST, whereas for development
f osteoporosis they were age and prolonged IST (P
01) (Figure 1B). The oldest quartile suffered most
ith 11 of 19 (median age: 46 years, range: 44-66;
ean T-score 2.3  0.5) developing osteoporosis
ersus 14 of 60 in the younger 3 quartiles (P  .01). A
imilar higher incidence of osteoporosis was noted
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eFigure 1. (A) Bone loss, and age and gender. (B) Bone loss in patients withhen age was grouped as  versus  median (P 
03). All 14 patients, 3 years from transplant on im-
unosuppression (steroids 6; calcineurin inhibitors 7,
irolimus 1) at the time of study had BL compared
ith 44 of 65 not on IST (P  .01). Similarly, 9 of
4 on IST versus 16 of 65 not on IST had osteo-
orosis (P  .008). There was no impact of gender,
iagnosis, BMT versus PBSCT, TBI versus no TBI,
BI dose 12 versus 13.6 Gy, disease risk (standard
r high), follow-up (continuous, short versus long;
0 versus  10 years follow-up), aGVHD, cGVHD
n development of overall BL or osteoporosis in
ong-term survivors.
Again, multivariate logistic regression analysis age
oldest quartile versus ﬁrst 3 quartiles odds ratio [OR]
.5, P  .03; age  versus  median OR 2.7, P  .45)
nd prolonged IST (OR 5.3, P  .01) were indepen-
ently associated with increased risk of osteoporosis
Table 2).
Male
Female
70
Normal score
Osteopenia
Osteoporosis
no cGVHD
history of cGVHD
150
On IST
Normal score
Osteopenia
Osteoporosis50
aiton
125
 96
18prolonged IST, chronic GVHD (cGVHD), and without cGVHD.
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Bone loss is a well-recognized complication of
CT, but there is a wide variations in reported inci-
ence (3%-52%) [2,3,5,8-13]. However. most previ-
us studies report bone density within the ﬁrst 2 years
ost-SCT [2,9-12]. Some studies address bone density
eyond 2 years, but very few beyond 5 years post-SCT
3,8,14]. The longest follow-up at 10 years only re-
orts osteoporosis-related ﬁndings from a question-
aire [3]. Our series is important because it is a de-
ailed site-speciﬁc analysis of BL at 7 anatomic sites
nd risk factor analysis of long term-survivors after
CT at a median follow-up beyond 5 years, describing
540 patient/year experience. The ﬁnding of a high
ate of BL in SCT patients who are cured of their
nderlying disease and who mostly have no other
omorbidities is of concern. As expected, older pa-
ients and those on prolonged IST for cGVHD suf-
ered severe BL irrespective of type of IST. However
ven in younger patients more than half had BL.
espite a high prevalence of BL, no patient in our
eries experienced fractures; however, it is possible
hat we might have missed asymptomatic fractures
ecause radiologic evaluation was performed only
hen clinically indicated. Similar to the study of Ker-
chan-Schind et al [14], we found no increase in BL
fter TBI-based MST compared to non-TBI based
CT.
The optimal management of BL after SCT is not
nown. Earlier studies have shown that BL occurs
mmediately after SCT [2,4,12] and recovery on
onger follow-up has been reported [2,3,13]. Treat-
ent of BL within 1-2 years after SCT with biphos-
honates appears promising with improvement in
one mass index at certain sites but without correction
n the hips [10,12] and femoral neck [12,13]. However,
he beneﬁt of treatment was lost when biphosphonates
ere stopped [12]. Furthermore, biphosphonates are
ssociated with increased risk of osteonecrosis of the
aw and safety data for prolonged biphosphonates after
CT is not available.
Our study draws attention to BL as a prevalent and
ersisting complication of SCT that outlasts cGVHD.
able 2. Signiﬁcant Factors Associated with Osteoporosis after
llogeneic Stem Cell Transplantation—Logistic Regression Analysis
Factor
Odd Ratio
(OR)
95% Confidence
Interval P
ge
First three quartile 1.0
Oldest quartile 3.5 1.1-11.4 .03
rolonged IST
No 1.00
Yes 5.3 1.3-21.2 .01
ST indiciates immunosuppressive therapy.t, therefore, appears important to continue to moni-or BL patterns life-long after SCT. Whether preven-
ion and treatment of BL is useful with either calcium/
itamin-D or addition of biphosphonates should be
etermined by prospective studies. In the absence of
ther data we have chosen conservative management
ith calcium/vitamin-D, reserving biphosphonates for
L worsening on serial follow-up or for additional
isk factors.
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